WASHINGTON, April 17 (Reuters) - Biopharmaceutical firm NeurogesX Inc. on Tuesday set its planned initial public offering at 4 million shares for an estimated price of $13 to $15 each.
WASHINGTON, April 17 (Reuters) - Biopharmaceutical firm NeurogesX Inc. on Tuesday set its planned initial public offering at 4 million shares for an estimated price of $13 to $15 each.